Drug Profile
Research programme: butyrylcholinesterase diagnostic agents - Treventis Corporation
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator TREVENTIS Corporation
- Class Cholinesterases; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Canada (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders(Diagnosis) in Canada (Parenteral, Injection)
- 26 Sep 2013 Preclinical trials in Alzheimer's disease (diagnosis) in Canada (Parenteral) before September 2013